Provided by Tiger Trade Technology Pte. Ltd.

Aprea Therapeutics, Inc.

0.9499
+0.144717.97%
Post-market: 0.98990.0400+4.21%18:37 EDT
Volume:2.13M
Turnover:2.00M
Market Cap:11.96M
PE:-1.01
High:0.9900
Open:0.8150
Low:0.8025
Close:0.8052
52wk High:1.69
52wk Low:0.5480
Shares:12.59M
Float Shares:7.91M
Volume Ratio:3.64
T/O Rate:26.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9400
EPS(LYR):-1.9269
ROE:-46.15%
ROA:-27.73%
PB:0.31
PE(LYR):-0.49

Loading ...

Aprea Therapeutics - Files for Resale of up to 5.5 Mln Shares by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
May 16

Aprea Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Aprea Therapeutics Q1 net loss narrows as R&D expenses fall

Reuters
·
May 13

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
May 13

Aprea Therapeutics Q1 EPS USD -0.22

THOMSON REUTERS
·
May 13

Top News Today: Stocks Mixed, Oil Rises After Hot Inflation Data

Dow Jones
·
May 13

Top News Today/Canada: Pet Valu Trims Outlook Amid Squeezed Margins

Dow Jones
·
May 13

Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
May 08

Aprea Therapeutics, Inc. :  Oppenheimer Initiates Coverage With Outperform Rating and Target Price $5

THOMSON REUTERS
·
May 07

Aprea Therapeutics files to sell 74.35M shares of common stock for holders

TIPRANKS
·
Apr 23

Aprea to present early Phase 1 data for WEE1 inhibitor APR-1051 at ASCO 2026

Reuters
·
Apr 21

Aprea Therapeutics to Provide Clinical Update on Acesot-1051 Phase 1 Trial Evaluating Wee1 Inhibitor, Apr-1051, at Asco 2026 Annual Meeting

THOMSON REUTERS
·
Apr 21

Aprea Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 20

Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE)

TIPRANKS
·
Apr 07

Aprea Therapeutics closes oversubscribed private placement raising $30 million gross proceeds

Reuters
·
Apr 01

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

THOMSON REUTERS
·
Apr 01

Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $1.2 From $4

THOMSON REUTERS
·
Mar 31

BRIEF-Aprea Therapeutics Highlights Positive Emerging Clinical Activity For Wee1 Inhibitor, Apr-1051

Reuters
·
Mar 30

Aprea Therapeutics announces oversubscribed private placement raising about $30 million

Reuters
·
Mar 30

Aprea reports confirmed partial response for APR-1051 in Phase 1 ACESOT-1051 trial

Reuters
·
Mar 30